Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Fate Therapeutics
(NQ:
FATE
)
3.840
+0.070 (+1.86%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,176,015
Open
3.830
Bid (Size)
3.810 (2)
Ask (Size)
3.930 (70)
Prev. Close
3.770
Today's Range
3.710 - 3.955
52wk Range
1.630 - 8.830
Shares Outstanding
98,384,456
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 13, 2024
FATE stock results show that Fate Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
August 13, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Performance
YTD
+4.07%
+4.07%
1 Month
-28.89%
-28.89%
3 Month
+8.47%
+8.47%
6 Month
-44.75%
-44.75%
1 Year
+46.01%
+46.01%
More News
Read More
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors
July 31, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Expert Outlook: Fate Therapeutics Through The Eyes Of 9 Analysts
June 17, 2024
Via
Benzinga
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
July 21, 2024
Via
The Motley Fool
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
July 16, 2024
Via
Benzinga
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
July 16, 2024
Via
Benzinga
Forecasting The Future: 8 Analyst Projections For Fate Therapeutics
May 06, 2024
Via
Benzinga
Where Fate Therapeutics Stands With Analysts
April 11, 2024
Via
Benzinga
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
This Best Buy Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
June 17, 2024
Via
Benzinga
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
June 04, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
May 29, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday
May 16, 2024
Via
Benzinga
FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 09, 2024
Via
InvestorPlace
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
May 09, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
May 09, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates
May 06, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
May 03, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
April 22, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
April 10, 2024
Via
Benzinga
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
March 19, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.